EGFR and non-small cell lung carcinoma: In patients with EGFR mutation-positive advanced NSCLC, there is an unmet need for EGFR-TKIs with improved central nervous system (CNS) penetration and activity against CNS metastases, either at initial diagnosis or time of progression [30].